

Parasites and drug resistance



**ADAM J. BIRKENHEUER,
DVM, PHD, DACVIM**

**NORTH CAROLINA STATE
UNIVERSITY COLLEGE OF
VETERINARY MEDICINE
RALEIGH, NC**

My Life



July 1, 1995: My first day as a veterinarian



I HATE research...



...but there are a lot of questions that
I want to answer




Hemolytic anemia, thrombocytopenia, hyperglobulinemia, icterus, fever, splenomegaly, and lymphadenopathy




How many dogs have it?




How extensive is the infection: 1995




How extensive is the infection: 2003



How extensive is the infection: 2012



**Typical living
conditions
of the
kennel dogs**



How is it transmitted?



- *Hypothesis: Babesia gibsoni* infections in the US are transmitted directly via dog bites and are not vector-transmitted
- APBT owners were not willing to give out information about previous bite wounds

Results

	<i>Babesia gibsoni</i>	<i>Babesia canis vogeli</i>	Other piroplasm
Total	131	11	3
APBT*	121	0	1
Greyhound	0	8	0
Other Breed	10	3	2

* APBT: American Pit Bull Terrier

Approach



- 15 *B. gibsoni* infected dogs that were not APBTs were identified
 - 3 excluded due to lack of known history
- 12 *Ehrlichia ewingii* infected dogs were used as a control group representing dogs with a tick-transmitted disease



Dog bite APBT* bite Ticks Housed with infected dog

<i>Babesia gibsoni</i>	9/12	9/12	2/12	4/12
<i>Ehrlichia ewingii</i>	3/12	0/12	5/12	2/12

* APBT: American Pit Bull Terrier

Results/Conclusions



- *B. gibsoni* infected dogs were more likely to have had a recent dog bite than *E. ewingii* infected dogs (Odds ratio 9.0; 95% CI 1.07 to 96.34; $p = 0.014$)
- The association was stronger ($p < 0.0001$) when the dog inflicting the bite was an APBT
- The association remained ($p = 0.045$) when each household with multiple infected dogs was counted as a single case

Now What?



- Developed test
- Identified epidemic
- Identified risk factors for infection
- **THERE IS NO EFFECTIVE TREATMENT FOR *Babesia gibsoni*!**

Treatment



- Treatments reduce morbidity and mortality but cannot clear the infections
 - Imidocarb, diminazene, trypan blue, phenamidine, doxycycline, clindamycin....
- Treated dogs are carriers and are at risk for recurrence of signs and can transmit infections to other dogs

Atovaquone and Azithromycin



- Atovaquone is a hydroxy-1,4-naphthoquinone: analog of ubiquinone and interferes with electron transport
- Azithromycin is an azalide antibiotic and interferes with protein synthesis
- Both drugs have anti-*Babesia* activity
- Together have been effective against other *Babesia* spp.

(Hughes 1995, Wittner 1996, Pudney 1997, Gray 1999, Krause 2000)

Specific Aim



- To determine whether or not an atovaquone and azithromycin drug combination would decrease *Babesia gibsoni* parasitemia below the limit of detection

Approach



- Double-blind placebo-controlled
 - 11 treatment
 - 11 placebo
- Could detect 60% difference between groups (based on pilot study)
- 3 post-treatment PCR tests
- CBC, biochemical profiles

Results

Dog	Group	Day 0	Day 60	Day 90	Day 120
1	Treatment	+	-	-	-
2	Treatment	+	-	-	-
3	Treatment	+	-	-	ND
4	Treatment	+	-	-	-
5	Treatment	+	-	-	-
6	Treatment	+	+	+	ND
7	Treatment	+	-	-	-
8	Treatment	+	-	-	-
9	Treatment	+	-	-	-
10	Treatment	+	-	-	-
11	Treatment	+	-	+	ND
12	Placebo	+	+	+	+
13	Placebo	+	+	ND	ND
14	Placebo	+	+	+	-
15	Placebo	+	+	+	+
16	Placebo	+	+	+	ND
17	Placebo	+	-	+	+
18	Placebo	+	+	+	+
19	Placebo	+	-	+	+
20	Placebo	+	+	+	+
21	Placebo	+	+	-	+
22	Placebo	+	+	+	+

+, positive PCR test

-, negative PCR test

ND, not determined

Results/Conclusions




- There was a significant difference between the treatment and placebo groups ($p= 0.0001$)
- No side-effects were reported in either the treatment or placebo treated dogs
- Only treatment reported to eliminate detectable *B. gibsoni* parasitemia

Mechanism Atovaquone Resistance?



CYTB protein
(363AA):



	120	130	140	150	250	260	270	280	290
<i>P. falciparum</i> cytb	FIVTAFVGYVLEW	QMSYWGATVITNL	LSSIPVAVI		PDNATVWNTYVTE	SCIVPEWYFIPFYAM	LFTVPSKEAGL	VIVLLSLQ	
<i>B. gibsoni</i> cytb	SMATAFLGYVLENG	QMSYWGATVITNLF	YWIPIDFVI		VDNSIESNPLQTP	LHIVPEWYLLTFYAT	LKLFPSKLAGLI	AMAALL	
<i>B. gibsoni</i> cytb_MUT	SMATAFLGYVLENG	QISYWGATVITNLF	YWIPIDFVI		VDNSIESNPLQTP	LHIVPEWYLLTFYAT	LKLFPSKLAGLI	AMAALL	

↑ *

Am. J. Trop. Med. Hyg., 74(4), 2006, pp. 593–597

Copyright © 2006 by The American Society of Tropical Medicine and Hygiene

SHORT REPORT: CLONING OF THE *BABESIA GIBSONI* CYTOCHROME B GENE AND ISOLATION OF THREE SINGLE NUCLEOTIDE POLYMORPHISMS FROM PARASITES PRESENT AFTER ATOVAQUONE TREATMENT

AYA MATSUU,* KAYOKO MIYAMOTO, HIROMI IKADAI, SHOZO OKANO, AND SEIICHI HIGUCHI

*Department of Small Animal Internal Medicine 1, Department of Veterinary Parasitology, and Department of Small Animal Surgery
3, School of Veterinary Medicine and Animal Sciences, Kitasato University, Aomori, Japan*

Possible Emergence of Drug-Resistant Variants of *Babesia gibsoni* in Clinical Cases Treated with Atovaquone and Azithromycin

M. Sakuma, A. Setoguchi, and Y. Endo

- 5/8 dogs relapsed after treatment
- ALL of the relapsed dogs had M121I mutation AFTER treatment

Molecular Epidemiological Survey of the *Babesia gibsoni* cytochrome *b* Gene in Western Japan

Masato SAKUMA¹⁾, Kenta FUKUDA²⁾, Katsuyoshi TAKAYAMA²⁾, Yukuharu KOBAYASHI²⁾, Takako SHIMOKAWA MIYAMA³⁾, Asuka SETOGUCHI¹⁾ and Yasuyuki ENDO¹⁾*

- Sequenced cytochrome B gene from 92 dogs with *B. gibsoni*
- NO previous treatment (not clear how this was confirmed)
- 3/92 dogs had M121I mutations

How is this possible if 5/8 dogs fail treatment?




Veterinary Parasitology 185 (2012) 145–150



Contents lists available at SciVerse ScienceDirect

Veterinary Parasitology

journal homepage: www.elsevier.com/locate/vetpar



Development of in vitro atovaquone-resistant *Babesia gibsoni* with a single-nucleotide polymorphism in *cytb*


Aiko Iguchi^a, Aya Matsuu^{a,*}, Hiromi Ikadai^b, Md. Hasanuzzaman Talukder^c, Yoshiaki Hikasa^a

In vitro atv-resistant strain



- They “induced” atv-resistance in vitro
- From wild-type and “cloned” strains
- M121 mutation was selected for NOT induced


Why the differences between USA and Asia?



August 10, 2003



- “Louise”
- 8 yr FS DSH
- **History-full** - Brought in by the pet sitter so some of recent history is unknown. Owners are out of town and she has left a message for them. Inside and outside kitty in a multi-cat household. Unsure of systems review but did see the cat eating on Thursday. Last night was laying around and somewhat unresponsive. Limp and wobbly this morning. (Drs. Birkenheuer & Concannon)





Louise died within 2 hours of admission

Cytauxzoon felis




- Tick-borne protozoan parasite that can fatally infect domestic cats and is harbored in bobcats
- Present in southeastern and south-central United States
- Discovered in 1976
- Only detected in carolinans in past decade
- Related to *Babesia*, *Theileria*, and *Plasmodium* species






Survival Post Infection: Historical Perspective

- **Initial discovery: believed to be 100% fatal**
- **Plum Island studies: 500 infected, 1 survived**
- **Current treatment with atovaquone and azithromycin: 60% survival**




Atovaquone Resistance

Atovaquone=anti-malarial drug that targets cytochrome *b* in the mitochondrial genome:



CYTB protein
(363AA):



Sick of hunting for one gene at a time



Features	<i>P. falciparum</i> [†]	<i>T. parva</i> [†]	<i>B. bovis</i> [†]	<i>B. gibsoni</i>	
				Genemark	Glimmer
Genome Size (Mbp)	22.8	8.3	8.2	7.5	7.5
G+C composition (%)	19.4	34.1	41.8	44	44
Protein Coding Genes	5,268	4,035	3,671	3,471	3,458
Average Protein Length	761	469	505	520	472
% Genes With Introns	53.9	73.6	61.5	68.65	61.1
Protein coding (%)	52.6	68.4	70.2	71.3	65

Features	<i>P. falciparum</i> ²	<i>B. bovis</i> ²	<i>T. parva</i> ²	<i>C. felis</i>	
				GeneMark	Glimmer
Genome Size (Mbp)	22.8	8.2	8.3	9.1	9.1
G+C Composition (%)	19.4	41.8	34.1	31.8	31.8
Protein Coding Genes	5,268	3,671	4,035	4,314	4,373
Average Protein (aa)	761	505	469	466.32	408.52
% Genes With Introns	53.9	61.5	73.6	68.65	61.1
Protein Coding (%)	52.6	70.2	68.4	66.2	68.8

Hypothesis



- *C. felis cytb* genotypes are associated with response (i.e. survival) to atovaquone and azithromycin treatment
- Cats that died were infected with *C. felis* strains that have missense mutations within or near the atovaquone binding site of the *cytb* gene.

Methods: Cats from Treatment Study



J Vet Intern Med 2011;25:55–60

Efficacy of Atovaquone and Azithromycin or Imidocarb Dipropionate in Cats with Acute *Cytauxzoonosis*

L.A. Cohn, A.J. Birkenheuer, J.D. Brunner, E.R. Ratcliff, and A.W. Craig

Background: Imidocarb or a combination of atovaquone and azithromycin (A&A) has been suggested for treatment of cats with cytauxzoonosis, but neither has been prospectively evaluated for efficacy.

Hypothesis/Objectives: That survival to hospital discharge is improved by treatment with A&A as compared with imidocarb.


45 cats with *C. felis* infection that were treated with atovaquone and azithromycin

- **28/45 (62%)** survived post treatment


Great idea! But...



***C. felis* *cytb* gene wasn't in our genome!**



PCR Assay



Cytb
gene
(1092
k

Sequence Analysis




Text File:

```
Onyx cytb MUT R
100      110      120
ATGCAATGGAGTTTGC AATGGAT
```

Chromatogram


Data: T_B_Mut_R*



RESULTS



High Diversity Present in *cytb* Gene



- 21 mutations: all substitutions
- 22 unique genotypes
- 4 mutations caused AA changes

Cytb Genotypes



Amino Acid Position	1	39	69	85	92	108	133	169	193	250	257	276	279	286	288	316	327	328	344	345	357	# Samples
Nucleotide Position	3	115	207	255	274	324	399	507	578	750	771	826	835	858	862	947	981	984	1032	1035	1071	
GENOTYPE																						
1	G	T	C	T	C	T	A	T	A	A	T	T	C	G	A	T	C	T	T	A	T	8
2	G	C	C	C	C	T	A	T	A	G	T	T	T	G	A	T	C	T	C	A	T	3
3	G	T	C	T	C	T	A	T	A	A	T	T	C	G	A	C	C	T	T	A	T	4
4	G	C	C	C	C	T	A	T	A	G	C	C	T	G	A	T	C	C	C	A	T	3
5	G	C	C	C	C	C	A	T	A	G	T	T	T	G	A	T	C	T	C	A	T	4
6	G	C	C	C	C	T	A	T	A	G	Y	Y	T	G	A	T	C	Y	C	A	T	2
7	G	Y	C	Y	C	Y	A	T	A	R	T	T	Y	G	A	T	C	T	Y	A	T	3
8	G	Y	C	Y	Y	T	A	T	A	R	T	T	C	G	A	T	C	T	Y	A	T	2
9	G	Y	C	Y	Y	Y	A	T	A	G	T	T	T	G	A	T	C	T	C	A	T	1
10	G	T	C	T	C	T	G	T	A	A	T	T	C	G	A	T	C	T	T	A	C	2
11	G	C	C	C	T	T	A	T	A	G	T	T	T	G	A	T	C	T	C	A	T	2
12	G	C	C	C	C	C	A	C	A	G	T	T	T	G	A	T	C	T	C	A	T	1
13	G	C	C	C	C	T	A	T	A	G	T	T	T	G	A	T	T	T	C	G	T	1
14	G	C	C	C	C	T	A	T	A	G	T	T	T	G	R	T	T	T	C	A	T	1
15	G	C	C	C	C	T	A	T	A	G	T	T	Y	G	A	T	C	Y	C	A	T	1
16	G	C	C	T	C	T	A	T	A	G	T	T	T	G	A	T	C	T	C	A	T	1
17	G	T	C	T	C	T	A	T	A	A	T	T	C	A	A	T	C	T	T	A	T	1
18	G	T	C	T	Y	T	A	T	A	A	T	T	C	G	A	T	C	T	T	A	T	1
19	G	Y	C	Y	C	T	A	T	A	R	T	T	C	G	A	T	C	T	Y	A	T	1
20	G	Y	C	Y	C	T	A	T	R	R	Y	Y	Y	G	A	T	C	Y	Y	A	T	1
21	G	Y	C	Y	Y	Y	A	Y	A	G	T	T	T	G	A	T	C	T	C	A	T	1
22	R	Y	Y	Y	C	Y	A	T	A	R	T	T	Y	G	A	T	C	T	Y	A	T	1

Survival is associated with WT *cytb* genotype

	Survived	Died	Total
WT	8	0	8
Non-WT	20	17	37
Total	28	17	45

p=0.017 Fisher's Exact Test, two-tailed p-value

...is this really associated with atovaquone treatment?

New aim introduced to study...



J Vet Intern Med 2011;25:55–60

Efficacy of Atovaquone and Azithromycin or Imidocarb Dipropionate in Cats with Acute Cytosporidiosis


L.A. Cohn, A.J. Birkenheuer, J.D. Brunker, E.R. Ratcliff, and A.W. Craig

Background: Imidocarb or a combination of atovaquone and azithromycin (A&A) has been suggested for treatment of cats with cytosporidiosis, but neither has been prospectively evaluated for efficacy.

Hypothesis/Objectives: That survival to hospital discharge is improved by treatment with A&A as compared with imidocarb.

- 24 additional cats** with *C. felis* infection that were treated with **imidocarb dipropionate**
- **7/24 (29%) survived post treatment**

Imidocarb Dipropionate Treatment Group



- 14 mutations (all substitutions)
- 8 more unique genotypes
- 6 mutations caused AA changes
- All samples: 35 mutations, 30 unique genotypes
- WT genotype represented in highest frequency (n=5); **but is there an association with survival?**

WT *cytb* genotype and survival appear to be associated with atovaquone/azithromycin treatment

Atovaquone and Azithromycin Imidocarb Dipropionate

	Survived	Died	Total
WT	8	0	8
Non-WT	20	17	37
Total	28	17	45


p=0.017

	Survived	Died	Total
WT	2	3	5
Non-WT	5	14	19
Total	7	17	24

p=0.608

- First part of hypothesis appears to be true: there is an association between *C. felis cytb* genotype and survival with atovaquone/azithromycin treatment
- But what about the second part of the hypothesis?

Hypothesis: Cats that died were infected with *C. felis* strains that **have missense mutations within or near the atovaquone binding site of the *cytb* gene.**



1 genotype with missense mutation in atovaquone binding site: cat *did* die

BUT...

16 other cats in this treatment group died without missense mutations

Missense mutations are not responsible for lack of response to atovaquone treatment!

How could the WT *cytb* genotype have an effect?



1. Transcription and translation
2. Could be linked to mutations in cytochrome oxidase or rRNA genes



Questions?



**I'z on yer
Pitbullz
controlling
their mindz.**



Questions?